TELA Bio (NASDAQ: TELA) grants director new stock and options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
TELA Bio, Inc. director Joseph H. Capper reported receiving new equity awards in the form of common stock and stock options as compensation. On June 9, 2026 he was granted 11,675 and 11,925 restricted stock units, and options for 17,335 and 17,550 shares at an exercise price of $0.935 per share expiring on June 9, 2036.
The restricted stock units vest over time, either in three equal annual installments beginning on June 9, 2027 or on the earlier of June 9, 2027, the next annual stockholder meeting, or a Change in Control under the company’s 2019 equity plan, in each case requiring continued service. Following these grants, one line shows 23,600 common shares and another 11,925 common shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
4 transactions reported
Mixed
4 txns
Insider
Capper Joseph H
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Stock Option (Right to Buy) | 17,550 | $0.00 | -- |
| Grant/Award | Stock Option (Right to Buy) | 17,335 | $0.00 | -- |
| Grant/Award | Common Stock | 11,925 | $0.00 | -- |
| Grant/Award | Common Stock | 11,675 | $0.00 | -- |
Holdings After Transaction:
Stock Option (Right to Buy) — 17,550 shares (Direct, null);
Common Stock — 11,925 shares (Direct, null)
Footnotes (1)
- These restricted stock units will vest in three equal annual installments beginning on June 9, 2027, in each case subject to the Reporting Person's continued service through the applicable vesting date. These restricted stock units vest on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date. The option vests in 36 equal monthly installments on each monthly anniversary of June 9, 2026, in each case subject to the Reporting Person's continued service through the applicable vesting date. The option vests on the earlier of (a) June 9, 2027, (b) the next annual meeting of stockholders, or (c) the occurrence of a Change in Control (as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan), in each case subject to the Reporting Person's continued service through the applicable vesting date.
Key Figures
RSU grant 1: 11,675 shares
RSU grant 2: 11,925 shares
Option grant 1 size: 17,335 shares
+5 more
8 metrics
RSU grant 1
11,675 shares
Restricted stock units granted June 9, 2026
RSU grant 2
11,925 shares
Restricted stock units granted June 9, 2026
Option grant 1 size
17,335 shares
Stock options granted June 9, 2026
Option grant 2 size
17,550 shares
Stock options granted June 9, 2026
Option exercise price
$0.935 per share
Exercise price for both option grants
Option expiration
June 9, 2036
Expiration date for both option grants
Shares following grant line 1
23,600 shares
Common stock held directly after first RSU grant
Shares following grant line 2
11,925 shares
Common stock held directly after second RSU grant
Key Terms
restricted stock units, Change in Control, Amended and Restated 2019 Equity Incentive Plan, Stock Option (Right to Buy), +1 more
5 terms
restricted stock units financial
"These restricted stock units will vest in three equal annual installments"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
Change in Control financial
"the occurrence of a Change in Control (as defined in the Issuer's Amended"
A "change in control" occurs when the ownership or management of a company shifts significantly, such as through a merger, acquisition, or sale of a large part of its assets. This change can impact how the company is run and may influence its future direction. For investors, it matters because it can affect the company's stability, strategy, and value, often signaling potential changes in investment risk or opportunity.
Amended and Restated 2019 Equity Incentive Plan financial
"as defined in the Issuer's Amended and Restated 2019 Equity Incentive Plan"
Stock Option (Right to Buy) financial
"security_title": "Stock Option (Right to Buy)""
vesting financial
"in each case subject to the Reporting Person's continued service through the applicable vesting date"
Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.
FAQ
What does the latest TELA (TELA) Form 4 filing report?
The Form 4 reports that director Joseph H. Capper received equity compensation grants. He was awarded restricted stock units and stock options in TELA Bio common stock, with vesting tied to continued board service and potential change in control events under the company’s equity plan.
How many restricted stock units did Joseph H. Capper receive from TELA Bio?
Joseph H. Capper received two restricted stock unit grants of 11,675 and 11,925 shares of TELA Bio common stock. These awards are structured to vest over time, subject to his continued service on the board through specified future vesting dates and potential corporate events.
What stock options were granted to Joseph H. Capper in the TELA Bio Form 4?
Capper was granted stock options covering 17,335 and 17,550 shares of TELA Bio common stock. These options have an exercise price of $0.935 per share and expire on June 9, 2036, providing long-term potential equity exposure if vesting and exercise conditions are met.
How do the restricted stock units and options for TELA (TELA) vest?
One RSU grant vests in three equal annual installments beginning June 9, 2027. The other RSUs and one option grant vest on the earlier of June 9, 2027, the next annual stockholder meeting, or a defined Change in Control, all requiring Capper’s continued service.
Is the TELA Bio Form 4 a buy or sell transaction by Joseph H. Capper?
The Form 4 reflects award grants, not open-market buying or selling. All four transactions are coded as acquisitions from the issuer, representing compensation in restricted stock units and stock options rather than discretionary market purchases or sales of TELA Bio shares.